Compare ALLO & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLO | REFI |
|---|---|---|
| Founded | 2017 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 255.6M |
| IPO Year | 2018 | 2021 |
| Metric | ALLO | REFI |
|---|---|---|
| Price | $1.69 | $11.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 1 |
| Target Price | $8.27 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 7.1M | 114.8K |
| Earning Date | 03-12-2026 | 03-11-2026 |
| Dividend Yield | N/A | ★ 17.02% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.69 |
| Revenue | N/A | ★ $54,287,847.00 |
| Revenue This Year | N/A | $13.69 |
| Revenue Next Year | N/A | $3.55 |
| P/E Ratio | ★ N/A | $7.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.86 | $11.85 |
| 52 Week High | $3.78 | $16.27 |
| Indicator | ALLO | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 37.36 |
| Support Level | $1.62 | $12.15 |
| Resistance Level | $1.97 | $12.49 |
| Average True Range (ATR) | 0.16 | 0.25 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 42.72 | 20.00 |
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.